niacinamide has been researched along with Coronary Heart Disease in 59 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied the acute haemodynamic dose response of nicorandil, a combined nitrate and potassium channel opener, in patients evaluated for chest pain." | 9.07 | Dose-related haemodynamic effects and pharmacokinetics of oral nicorandil in patients evaluated for chest pain. ( Arnold, JM; Hearron, AE; Jungbluth, GL; Kowey, PR; Luderer, JR; Wolf, DL, 1994) |
| "Patients with stable, effort-induced angina pectoris and a typical combination of anginal pain and ischemic ST depression in exercise tolerance tests were randomized to treatment for 8 weeks with nicorandil (a newly developed antianginal and anti-ischemic drug) or nifedipine." | 9.07 | Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. ( Diderholm, E; Frithz, G; Gudbrandsson, T; Hedbäck, B; Höglund, C; Moelstad, P; Perk, J; Sverrisson, JT; Ulvenstam, G, 1992) |
| "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem." | 7.69 | Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis. ( Araki, H; Higuchi, S; Kishi-Tanikawa, S; Takahashi, K; Takahashi, T; Tsuchida, K, 1996) |
| "The effects of nicorandil, a new antianginal drug, on size of myocardial infarction were studied in anesthetized, open-chest dogs after left anterior descending coronary artery occlusion." | 7.67 | Reduction of size of myocardial infarction with nicorandil, a new antianginal drug, after coronary artery occlusion in dogs. ( Endo, T; Fujita, S; Hayakawa, H; Kikuchi, K; Kiuchi, K; Nejima, J; Okumura, H, 1988) |
| " The most often reported adverse event was headache, which was responsible for most of the study withdrawals due to clinical intolerance (9." | 6.68 | Nicorandil safety in the long-term treatment of coronary heart disease. ( Darmon, JY; Witchitz, S, 1995) |
| " Under the assumption that the repetitive administration of nitrates with short dosing intervals might induce the development of tolerance to the nitrate mechanism of action, the t." | 6.67 | Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. ( Döring, G, 1992) |
| "We studied the acute haemodynamic dose response of nicorandil, a combined nitrate and potassium channel opener, in patients evaluated for chest pain." | 5.07 | Dose-related haemodynamic effects and pharmacokinetics of oral nicorandil in patients evaluated for chest pain. ( Arnold, JM; Hearron, AE; Jungbluth, GL; Kowey, PR; Luderer, JR; Wolf, DL, 1994) |
| "This randomized, double-blind, parallel study compared the anti-anginal effects of nicorandil and atenolol in 37 patients with exercise-induced angina pectoris." | 5.07 | A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina. ( Hughes, LO; Lahiri, A; Raftery, EB; Rose, EL, 1993) |
| "Patients with stable, effort-induced angina pectoris and a typical combination of anginal pain and ischemic ST depression in exercise tolerance tests were randomized to treatment for 8 weeks with nicorandil (a newly developed antianginal and anti-ischemic drug) or nifedipine." | 5.07 | Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. ( Diderholm, E; Frithz, G; Gudbrandsson, T; Hedbäck, B; Höglund, C; Moelstad, P; Perk, J; Sverrisson, JT; Ulvenstam, G, 1992) |
| "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem." | 3.69 | Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis. ( Araki, H; Higuchi, S; Kishi-Tanikawa, S; Takahashi, K; Takahashi, T; Tsuchida, K, 1996) |
| "The effects of nicorandil, a new antianginal drug, on size of myocardial infarction were studied in anesthetized, open-chest dogs after left anterior descending coronary artery occlusion." | 3.67 | Reduction of size of myocardial infarction with nicorandil, a new antianginal drug, after coronary artery occlusion in dogs. ( Endo, T; Fujita, S; Hayakawa, H; Kikuchi, K; Kiuchi, K; Nejima, J; Okumura, H, 1988) |
| " The most often reported adverse event was headache, which was responsible for most of the study withdrawals due to clinical intolerance (9." | 2.68 | Nicorandil safety in the long-term treatment of coronary heart disease. ( Darmon, JY; Witchitz, S, 1995) |
| "Nicorandil was found to increase the rate of VO2, increase during the onset of constant work rate exercise, probably as a result of an improved response in cardiac output." | 2.68 | Effects of nicorandil on kinetics of oxygen uptake at the onset of exercise in patients with coronary artery disease. ( Adachi, H; Hiroe, M; Kano, H; Koike, A; Korenaga, M; Marumo, F; Miyahara, Y; Shimizu, N; Sugimoto, K; Yajima, T, 1995) |
| "Nicorandil is an antianginal drug that causes potent coronary vasodilation of both epicardial and resistance vessels." | 2.68 | Coronary microvascular response to intracoronary administration of nicorandil. ( Hongo, M; Nakatsuka, T; Sekiguchi, M; Takenaka, H; Uchikawa, S; Watanabe, N, 1995) |
| "Nicorandil is a hybrid of a nitrate and a potassium channel opener, and has a potent vasodilatory effect on coronary arteries." | 2.68 | Effective and safe dose of intracoronary nicorandil in man. ( Fujita, M; Igawa, A; Inouc, H; Miwa, K; Yamanishi, K, 1995) |
| "Nicorandil and diltiazem were both found to decrease the frequency of anginal attacks and the consumption of nitroglycerin tablets (P < 0." | 2.67 | A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. ( Blin, P; Guermonprez, JL; Peterlongo, F, 1993) |
| " Under the assumption that the repetitive administration of nitrates with short dosing intervals might induce the development of tolerance to the nitrate mechanism of action, the t." | 2.67 | Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. ( Döring, G, 1992) |
| " Clinical trials demonstrate that chronic administration of nicorandil can significantly increase exercise tolerance in patients with coronary artery disease." | 2.38 | [Anti-angina activity of potassium-channel activators]. ( Ambrosio, G; Chiariello, M; Duilio, C, 1993) |
| "Nicorandil is a potent vasodilator with antianginal and anti-ischemic properties that acts on both the coronary and the peripheral vascular bed." | 2.38 | Acute hemodynamic effects of nicorandil in coronary artery disease. ( Erbel, R; Meyer, J; Treese, N, 1992) |
| "nicorandil was significant, the 8% increase of isosorbide dinitrate was not." | 1.28 | Nicorandil and cardiovascular performance in patients with coronary artery disease. ( MacLeod, D; Suryapranata, H, 1992) |
| "Nicorandil was administered either intravenously (i." | 1.28 | Nicorandil improves postischemic contractile function independently of direct myocardial effects. ( Grover, GJ; Parham, CS; Sleph, PG, 1990) |
| "Nicorandil, 20 mg, was administered sublingually to 11 consecutive patients and 40 mg to 11 others." | 1.28 | Coronary vasodilatory action after nicorandil: a quantitative angiographic study. ( Serruys, PW; Suryapranata, H, 1989) |
| "Nicorandil was thus considered to produce its antianginal effect primarily by redistribution of coronary blood flow as a result of dilatation of vascular beds and by its antispasmodic action." | 1.27 | Effects of nicorandil on coronary circulation in patients with ischemic heart disease: comparison with nitroglycerin. ( Aizawa, T; Kato, K; Ogasawara, K, 1987) |
| "Nicorandil, 20 mg, was administered sublingually to 11 consecutive patients and 40 mg to 11 others." | 1.27 | Coronary vasodilatory action after a single dose of nicorandil. ( De Feyter, PJ; Hugenholtz, PG; Serruys, PW; Suryapranata, H; Verdouw, PD, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (52.54) | 18.7374 |
| 1990's | 28 (47.46) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| GHIA, G | 1 |
| MEREU, D | 1 |
| MACCARINI, PA | 1 |
| FREZZA, S | 1 |
| Thormann, J | 1 |
| Schlepper, M | 1 |
| Kramer, W | 1 |
| Gottwik, M | 1 |
| Abiko, Y | 2 |
| Nishimura, T | 1 |
| Sakai, K | 2 |
| Lamping, KA | 1 |
| Warltier, DC | 3 |
| Hardman, HF | 1 |
| Gross, GJ | 5 |
| Witchitz, S | 1 |
| Darmon, JY | 1 |
| Koike, A | 1 |
| Hiroe, M | 1 |
| Yajima, T | 1 |
| Adachi, H | 1 |
| Shimizu, N | 1 |
| Kano, H | 1 |
| Sugimoto, K | 1 |
| Miyahara, Y | 1 |
| Korenaga, M | 1 |
| Marumo, F | 1 |
| Hongo, M | 1 |
| Takenaka, H | 1 |
| Uchikawa, S | 1 |
| Nakatsuka, T | 1 |
| Watanabe, N | 1 |
| Sekiguchi, M | 1 |
| Haeusler, G | 1 |
| Lues, I | 1 |
| Chiariello, M | 1 |
| Duilio, C | 1 |
| Ambrosio, G | 1 |
| Arnold, JM | 1 |
| Kowey, PR | 1 |
| Wolf, DL | 1 |
| Jungbluth, GL | 1 |
| Hearron, AE | 1 |
| Luderer, JR | 1 |
| Suryapranata, H | 4 |
| Why, HJ | 1 |
| Richardson, PJ | 1 |
| Guermonprez, JL | 1 |
| Blin, P | 1 |
| Peterlongo, F | 1 |
| Raftery, EB | 1 |
| Lahiri, A | 1 |
| Hughes, LO | 1 |
| Rose, EL | 1 |
| Kato, K | 2 |
| Miwa, K | 1 |
| Igawa, A | 1 |
| Yamanishi, K | 1 |
| Fujita, M | 1 |
| Inouc, H | 1 |
| Takahashi, T | 1 |
| Takahashi, K | 1 |
| Kishi-Tanikawa, S | 1 |
| Tsuchida, K | 1 |
| Araki, H | 1 |
| Higuchi, S | 1 |
| Goldschmidt, M | 1 |
| Landzberg, BR | 1 |
| Frishman, WH | 1 |
| Murayama, S | 1 |
| Yamakado, T | 1 |
| Nakano, T | 1 |
| Takaoka, A | 1 |
| Nakae, I | 1 |
| Liu, Q | 1 |
| Yamamoto, K | 1 |
| Ito, M | 1 |
| Kinoshita, M | 1 |
| Nishikawa, Y | 1 |
| Kanki, H | 1 |
| Ogawa, S | 1 |
| MacLeod, D | 1 |
| Treese, N | 1 |
| Erbel, R | 1 |
| Meyer, J | 1 |
| Ulvenstam, G | 1 |
| Diderholm, E | 1 |
| Frithz, G | 1 |
| Gudbrandsson, T | 1 |
| Hedbäck, B | 1 |
| Höglund, C | 1 |
| Moelstad, P | 1 |
| Perk, J | 1 |
| Sverrisson, JT | 1 |
| Döring, G | 1 |
| Ogino, K | 1 |
| Kinugawa, T | 1 |
| Noguchi, N | 1 |
| Kitamura, H | 1 |
| Matsumoto, T | 1 |
| Miyakoda, H | 1 |
| Kotake, H | 1 |
| Mashiba, H | 1 |
| Grover, GJ | 1 |
| Sleph, PG | 1 |
| Parham, CS | 1 |
| Mitani, A | 1 |
| Kinoshita, K | 1 |
| Fukamachi, K | 1 |
| Sakamoto, M | 1 |
| Kurisu, K | 1 |
| Tsuruhara, Y | 1 |
| Fukumura, F | 1 |
| Nakashima, A | 1 |
| Tokunaga, K | 1 |
| Ohta, H | 1 |
| Jinno, Y | 1 |
| Harada, K | 1 |
| Ogawa, N | 1 |
| Fukushima, H | 1 |
| Nishikori, K | 1 |
| Kishida, H | 1 |
| Hata, N | 1 |
| Kusama, Y | 1 |
| Iwahara, S | 1 |
| Sasaki, Y | 1 |
| Mori, N | 1 |
| Yasutake, M | 1 |
| Koumi, S | 1 |
| Takayama, M | 1 |
| Munakata, K | 1 |
| Tsuchioka, Y | 1 |
| Yamagata, T | 1 |
| Amioka, H | 1 |
| Hashimoto, M | 1 |
| Okamoto, M | 1 |
| Matsuura, H | 1 |
| Kajiyama, G | 1 |
| Chen, SL | 1 |
| Zhu, MZ | 1 |
| Feng, XB | 1 |
| Li, LS | 1 |
| Zang, YM | 1 |
| Kambara, H | 2 |
| Nakamura, Y | 3 |
| Tamaki, S | 2 |
| Kawai, C | 2 |
| Kobayashi, K | 1 |
| Hakuta, T | 1 |
| Aizawa, T | 1 |
| Ogasawara, K | 1 |
| Pieper, GM | 3 |
| Ichihara, K | 2 |
| Kojima, S | 1 |
| Mori, H | 1 |
| Abe, S | 1 |
| Miyamori, R | 1 |
| Miyazaki, T | 1 |
| Sakurai, K | 1 |
| Hattori, S | 1 |
| Takahashi, M | 1 |
| Endo, T | 1 |
| Nejima, J | 1 |
| Kiuchi, K | 1 |
| Fujita, S | 1 |
| Kikuchi, K | 1 |
| Hayakawa, H | 1 |
| Okumura, H | 1 |
| Haneda, T | 1 |
| Onodera, S | 1 |
| Gross, G | 1 |
| Pieper, G | 1 |
| Farber, NE | 1 |
| Warltier, D | 1 |
| Hardman, H | 1 |
| Coltart, DJ | 1 |
| Signy, M | 1 |
| Serruys, PW | 2 |
| Kempsford, RD | 1 |
| Hawgood, BJ | 1 |
| Sassen, LM | 1 |
| Soei, LK | 1 |
| Heere, TJ | 1 |
| van Woerkens, LJ | 1 |
| Saxena, PR | 1 |
| Verdouw, PD | 2 |
| Katagiri, T | 1 |
| Mochizuki, M | 1 |
| Umetsu, K | 1 |
| Hiroshige, J | 1 |
| Geshi, E | 1 |
| Konno, N | 1 |
| Gubachev, IuM | 1 |
| Vinokur, VA | 1 |
| Dornichev, VM | 1 |
| Shimshak, TM | 1 |
| Preuss, KC | 1 |
| Brooks, HL | 1 |
| De Feyter, PJ | 1 |
| Hugenholtz, PG | 1 |
| Irié, H | 1 |
| Korb, H | 1 |
| Hoeft, A | 1 |
| Hunneman, DH | 1 |
| Schraeder, R | 1 |
| Wolpers, HG | 1 |
| Hellige, G | 1 |
| Wren, JC | 1 |
| Vittori, C | 1 |
| Borri, P | 1 |
| Bianchi, V | 1 |
| Caruzzo, C | 1 |
| Khalfer, ESh | 1 |
| Iakusheva, IA | 1 |
| Katkova, NB | 1 |
| Loginova, LA | 1 |
| Ital'ianskaia, IuV | 1 |
8 reviews available for niacinamide and Coronary Heart Disease
| Article | Year |
|---|---|
Therapeutic potential of potassium channel activators in coronary heart disease.
Topics: Animals; Coronary Disease; Coronary Vessels; Heart; Humans; Muscle, Smooth, Vascular; Niacinamide; N | 1994 |
[Anti-angina activity of potassium-channel activators].
Topics: Angina Pectoris; Clinical Trials as Topic; Coronary Disease; Humans; Niacinamide; Nicorandil; Potass | 1993 |
Coronary haemodynamics and vasodilatory profile of a potassium channel opener in patients with coronary artery disease.
Topics: Administration, Sublingual; Coronary Circulation; Coronary Disease; Dose-Response Relationship, Drug | 1993 |
A potassium channel opener as monotherapy in chronic stable angina pectoris: comparison with placebo.
Topics: Angina Pectoris; Coronary Circulation; Coronary Disease; Dose-Response Relationship, Drug; Exercise | 1993 |
Haemodynamic and clinical effects of an intravenous potassium channel opener--a review.
Topics: Administration, Sublingual; Angina, Unstable; Coronary Circulation; Coronary Disease; Hemodynamics; | 1993 |
Nicorandil: a potassium channel opening drug for treatment of ischemic heart disease.
Topics: Clinical Trials as Topic; Coronary Disease; Hemodynamics; Humans; Muscle, Smooth, Vascular; Niacinam | 1996 |
Acute hemodynamic effects of nicorandil in coronary artery disease.
Topics: Animals; Coronary Disease; Dogs; Hemodynamics; Humans; Niacinamide; Nicorandil; Vasodilator Agents | 1992 |
Effects of nicorandil on coronary circulation and myocardial ischemia.
Topics: Animals; Coronary Circulation; Coronary Disease; Dogs; Niacinamide; Nicorandil; Vasodilator Agents | 1989 |
11 trials available for niacinamide and Coronary Heart Disease
| Article | Year |
|---|---|
Nicorandil safety in the long-term treatment of coronary heart disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Blood Pressure; | 1995 |
Effects of nicorandil on kinetics of oxygen uptake at the onset of exercise in patients with coronary artery disease.
Topics: Adult; Aged; Coronary Disease; Cross-Over Studies; Double-Blind Method; Exercise; Exercise Test; Fem | 1995 |
Coronary microvascular response to intracoronary administration of nicorandil.
Topics: Adult; Aged; Angina Pectoris; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Coronary | 1995 |
Dose-related haemodynamic effects and pharmacokinetics of oral nicorandil in patients evaluated for chest pain.
Topics: Analysis of Variance; Cardiac Catheterization; Chest Pain; Coronary Disease; Dose-Response Relations | 1994 |
A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris.
Topics: Aged; Angina Pectoris; Coronary Circulation; Coronary Disease; Diltiazem; Dose-Response Relationship | 1993 |
A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina.
Topics: Aged; Angina Pectoris; Atenolol; Blood Pressure; Coronary Circulation; Coronary Disease; Double-Blin | 1993 |
Effective and safe dose of intracoronary nicorandil in man.
Topics: Aged; Coronary Angiography; Coronary Disease; Coronary Vessels; Dose-Response Relationship, Drug; Fe | 1995 |
Effects of nicorandil, an antianginal potassium channel opener, on left ventricular systolic and diastolic function in patients with chronic coronary artery disease.
Topics: Adult; Aged; Chronic Disease; Coronary Disease; Diastole; Female; Humans; Male; Middle Aged; Niacina | 1997 |
Differential effects of N-acetylcysteine on nitroglycerin- and nicorandil-induced vasodilation in human coronary circulation.
Topics: Acetylcysteine; Coronary Circulation; Coronary Disease; Coronary Vessels; Female; Free Radical Scave | 1998 |
Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Coronary Disease; Double-Blind Method; Electrocardiogr | 1992 |
Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients.
Topics: Adult; Aged; Blood Pressure; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Ex | 1992 |
40 other studies available for niacinamide and Coronary Heart Disease
| Article | Year |
|---|---|
[CLINICAL OBSERVATIONS AND THERAPEUTIC RESULTS IN SUBJECTS WITH ISCHEMIC CARDIOPATHY TREATED WITH AN ENZYME COMPLEX ASSOCIATED WITH A VASODILATOR DRUG].
Topics: Adenosine Triphosphate; Coronary Disease; Drug Therapy; Electrocardiography; Flavin Mononucleotide; | 1964 |
[ON THE CLINICAL VALUE OF COLLATERAL TROPHO-ENZYMATIC THERAPY IN ACUTE AND CHRONIC HEART DISEASES].
Topics: Coenzymes; Coronary Disease; Heart Diseases; Humans; Hypertension; Khellin; Niacin; Niacinamide; Pul | 1964 |
[Efficacy of nicorandil (SG-75), a substance with nitro-properties and long-term effects in coronary patients: improvement of LV-function and wall motility without pacing-induced myocardial ischemia].
Topics: Aged; Angiography; Cardiac Pacing, Artificial; Coronary Disease; Heart Ventricles; Hemodynamics; Hum | 1982 |
Nicorandil attenuates myocardial acidosis during coronary occlusion in dogs.
Topics: Acidosis; Animals; Coronary Disease; Dogs; Female; Heart Diseases; Male; Niacinamide; Nicorandil; Va | 1984 |
Effects of nicorandil, a new antianginal agent, and nifedipine on collateral blood flow in a chronic coronary occlusion model.
Topics: Animals; Collateral Circulation; Coronary Circulation; Coronary Disease; Disease Models, Animal; Dog | 1984 |
Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
Topics: Angina Pectoris; Animals; Calcium Channel Blockers; Coronary Circulation; Coronary Disease; Diltiaze | 1996 |
Nicorandil improves ischemic changes in epicardial ECG during short-term coronary occlusion by opening ATP-sensitive potassium channels in pigs.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Coronary Circulation; Coronary Disease; Electroc | 1997 |
Nicorandil and cardiovascular performance in patients with coronary artery disease.
Topics: Administration, Sublingual; Coronary Circulation; Coronary Disease; Female; Hemodynamics; Humans; Is | 1992 |
Suppression of sympathetic nervous system activity by nicorandil during exercise.
Topics: Adult; Aged; Coronary Disease; Depression, Chemical; Electroencephalography; Epinephrine; Exercise; | 1992 |
Nicorandil improves postischemic contractile function independently of direct myocardial effects.
Topics: Animals; Benzopyrans; Coronary Circulation; Coronary Disease; Cromakalim; Dogs; Heart Function Tests | 1990 |
Effects of glibenclamide and nicorandil on cardiac function during ischemia and reperfusion in isolated perfused rat hearts.
Topics: Adenosine Triphosphate; Animals; Coronary Disease; Glyburide; Heart; Kinetics; Male; Myocardial Cont | 1991 |
Cardioprotective effects of KRN2391 and nicorandil on ischemic dysfunction in perfused rat heart.
Topics: Animals; Coronary Disease; Cytosol; Glyburide; Heart Rate; In Vitro Techniques; Male; Myocardium; Ni | 1991 |
Angiographic response to a vasodilating drug, nicorandil, in patients with coronary artery disease.
Topics: Administration, Sublingual; Adult; Aged; Coronary Angiography; Coronary Disease; Coronary Vessels; F | 1990 |
[Clinical electrophysiological effects of nicorandil on the conduction system in humans].
Topics: Coronary Disease; Electrophysiology; Female; Heart Conduction System; Heart Rate; Humans; Male; Midd | 1990 |
[Effect of nicorandil on coronary circulation in ischemic region].
Topics: Animals; Blood Viscosity; Coronary Circulation; Coronary Disease; Dogs; Female; Hemodynamics; Infusi | 1990 |
Beneficial effects of nicorandil on cardiovascular hemodynamics and left ventricular function.
Topics: Angina Pectoris; Cardiac Catheterization; Cardiac Pacing, Artificial; Coronary Disease; Female; Hear | 1987 |
Effects of nicorandil on coronary hemodynamics in ischemic heart disease: comparison with nitroglycerin, nifedipine, and propranolol.
Topics: Adult; Aged; Cardiac Pacing, Artificial; Coronary Circulation; Coronary Disease; Hemodynamics; Human | 1987 |
Effects of nicorandil on coronary circulation in patients with ischemic heart disease: comparison with nitroglycerin.
Topics: Coronary Circulation; Coronary Disease; Coronary Vasospasm; Female; Hemodynamics; Humans; Male; Midd | 1987 |
Comparative effects of nicorandil, nitroglycerin, nicotinic acid, and SG-86 on the metabolic status and functional recovery of the ischemic-reperfused myocardium.
Topics: Animals; Coronary Circulation; Coronary Disease; Dogs; Fatty Acids, Nonesterified; Female; Glucose; | 1987 |
Effects of nicorandil and other antianginal drugs on myocardial pH in the ischemic dog heart.
Topics: Acidosis; Animals; Coronary Disease; Diltiazem; Dogs; Hydrogen-Ion Concentration; In Vitro Technique | 1987 |
Examination of the direct effects of nicorandil, verapamil, propranolol, and nitroglycerin on the hypoxic canine myocardium.
Topics: Animals; Coronary Disease; Dogs; Female; Hemodynamics; In Vitro Techniques; Male; Myocardium; Niacin | 1987 |
Reduction of size of myocardial infarction with nicorandil, a new antianginal drug, after coronary artery occlusion in dogs.
Topics: Animals; Coronary Disease; Dogs; Female; Hemodynamics; Male; Myocardial Infarction; Niacinamide; Nic | 1988 |
Effects of nicorandil and nipradilol on ischemic myocardium in perfused rat heart.
Topics: Adenosine Triphosphate; Animals; Blood Pressure; Coronary Circulation; Coronary Disease; Heart; In V | 1989 |
Acute hemodynamic effects of single-dose nicorandil in coronary artery disease.
Topics: Administration, Oral; Administration, Sublingual; Adult; Coronary Disease; Female; Hemodynamics; Hum | 1989 |
Effects of intravenous administration of nicorandil on cardiovascular hemodynamics and left ventricular function.
Topics: Aged; Coronary Disease; Female; Hemodynamics; Humans; Injections, Intravenous; Male; Middle Aged; My | 1989 |
Coronary vasodilatory action after nicorandil: a quantitative angiographic study.
Topics: Administration, Sublingual; Adult; Aged; Angiography; Coronary Angiography; Coronary Disease; Corona | 1989 |
Assessment of the antiarrhythmic activity of nicorandil during myocardial ischemia and reperfusion.
Topics: Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Coronary Circulation; Coronary Disease; Ele | 1989 |
Protective effect of nicorandil on postischemic function and tissue adenine nucleotides following a brief period of low-flow global ischemia in the isolated perfused rat heart.
Topics: Adenine Nucleotides; Animals; Coronary Disease; Epoprostenol; Heart; Heart Function Tests; In Vitro | 1989 |
Nicorandil and cardiovascular performance in anaesthetized pigs with a concentric coronary artery stenosis.
Topics: Anesthesia; Animals; Arrhythmias, Cardiac; Coronary Disease; Heart Conduction System; Heart Function | 1989 |
Protection of acute ischemic myocardial injury by pharmacological intervention.
Topics: Adenosine Triphosphatases; Adrenergic alpha-Antagonists; Animals; Calcium; Calcium-Transporting ATPa | 1989 |
[Effect of nicotinamide on neurohumoral regulation and lipid peroxidation in ischemic heart disease].
Topics: Adult; Antioxidants; Coronary Disease; Cyclic AMP; Cyclic GMP; Humans; Lipid Peroxides; Male; Middle | 1988 |
Recovery of contractile function in post-ischaemic reperfused myocardium of conscious dogs: influence of nicorandil, a new antianginal agent.
Topics: Animals; Blood Pressure; Coronary Disease; Dogs; Female; Heart; Heart Rate; Male; Myocardial Contrac | 1986 |
Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Animals; Coronary Circulation; Coronary Disease; Dogs; | 1987 |
Coronary vasodilatory action after a single dose of nicorandil.
Topics: Adult; Aged; Blood Pressure; Coronary Angiography; Coronary Circulation; Coronary Disease; Coronary | 1988 |
Experimental studies on ischemic injury and reperfusion injury to the cardiac sarcoplasmic reticulum--the myocardial protective effect of nicorandil.
Topics: Animals; Blood Pressure; Calcium; Cardiac Output; Cardioplegic Solutions; Cardiopulmonary Bypass; Co | 1988 |
Effectiveness of nicorandil in the preservation of myocardium stressed by transient ischemia and its influence on cardiac metabolism during coronary artery occlusion with subsequent reperfusion: a comparison with isosorbide dinitrate.
Topics: Animals; Coronary Disease; Coronary Vessels; Dogs; Fatty Acids, Nonesterified; Glucose; Heart; Hemod | 1985 |
Thyroid function and coronary atherosclerosis.
Topics: Adult; Aged; Arteriosclerosis; Ascorbic Acid; Calcium; Cholesterol; Coronary Disease; Electrocardiog | 1968 |
[On the comparative results of the use of Clarisco in peripheral vascular diseases].
Topics: Aged; Arteriosclerosis Obliterans; Choline; Coronary Disease; Folic Acid; Gangrene; Heparin; Humans; | 1970 |
[Anti-hyperlipemic therapy in the secondary prevention of coronary heart disease. Long-term study].
Topics: Clofibrate; Coronary Disease; Female; Humans; Hyperlipidemias; Male; Niacinamide; Nicotinic Acids; P | 1974 |
[Phosphorus compounds and their metabolites in ischemic heart diseases].
Topics: Adenine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphatases; Adenosine Tripho | 1974 |